How has been the historical performance of Sotac Pharma.?

Answer:The historical performance of Sotac Pharma shows a fluctuating trend in net sales and profitability over the past five years.

Breakdown:
Sotac Pharma's net sales peaked at 103.83 Cr in March 2024 but declined to 96.99 Cr by March 2025, following a steady increase from 28.60 Cr in March 2020 to 77.48 Cr in March 2023. Total operating income mirrored this trend, reaching 96.99 Cr in March 2025. The company experienced a significant reduction in raw material costs from 77.76 Cr in March 2024 to 62.93 Cr in March 2025, contributing to an operating profit (PBDIT) of 17.55 Cr in March 2025, up from 9.00 Cr in the previous year. Profit before tax also saw a notable increase to 11.12 Cr in March 2025, compared to 3.96 Cr in March 2024, leading to a profit after tax of 9.28 Cr. The earnings per share rose to 7.27 in March 2025, reflecting improved profitability. On the balance sheet, total assets increased to 123.03 Cr in March 2025, with total liabilities also rising to 43.70 Cr. Cash flow from operating activities remained negative at -4.00 Cr in March 2025, although financing activities generated a positive cash flow of 16.00 Cr. Overall, Sotac Pharma's performance indicates growth in sales and profitability, despite challenges in cash flow management.